Formosa Pharmaceuticals, Inc.

6838

TW0006838006

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
55.4 ^TWD	+1.65%		+0.36%	+10.91%

May. 09	Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	CI
Mar. 07	Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	CI

Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022

August 11, 2022 at 02:43 am EDT

Formosa Pharmaceuticals, Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 0.336 million compared to TWD 28.23 million a year ago. Net loss was TWD 203.08 million compared to TWD 184.9 million a year ago.

Basic loss per share from continuing operations was TWD 2.05 compared to TWD 2.14 a year ago.

Latest news about Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	May. 09	CI
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	Mar. 07	CI
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery	Mar. 05	CI
US FDA approves Eyenovia's eye drug, Formosa Pharma says	Mar. 04	RE
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	Jan. 26	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 05	CI
Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index	23-09-18	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery	23-05-04	CI
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials	23-04-12	MT
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint	23-04-11	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics	23-02-15	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery	22-08-09	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery	22-05-12	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs	22-03-06	CI
China Grand Pharmaceutical and Healthcare Holdings Limited Announces That the Group Recently Reached an Exclusive Product Licensing Agreement with Formosa Pharmaceuticals, Inc	21-06-03	CI
Formosa Pharmaceuticals, Inc. completed the acquisition of Activus Pharma Co., Ltd. from Sosei Group Corporation.	17-08-09	CI
Formosa Pharmaceuticals, Inc. agreed to acquire Activus Pharma Co., Ltd. from Sosei Group Corporation for approximately TWD 370 million.	17-08-03	CI

Chart Formosa Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FORMOSA PHARMACEUTICALS, INC.	+10.91%	225M
ELI LILLY AND COMPANY	+59.97%	827B
NOVO NORDISK A/S	+38.38%	634B
JOHNSON & JOHNSON	-6.18%	350B
MERCK & CO., INC.	+15.61%	319B
ABBVIE INC.	+8.44%	294B
ASTRAZENECA PLC	+12.68%	240B
NOVARTIS AG	+14.40%	221B
ROCHE HOLDING AG	+0.04%	219B
AMGEN INC.	+9.68%	167B